Levels of the first-phase insulin secretion deficiency as a predictor for type 2 diabetes onset by using clinical-metabolic models

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Aims: Type 2 diabetes mellitus (T2DM) is characterized by both decreased insulin sensitivity and impaired insulin secretion. The 2 phases of insulin secretion are the first-phase insulin secretion (1st ISEC) and the secondphase insulin secretion. In this study, we tried to build clinical-metabolic models to predict the 1st ISEC deficiency (ISEC-D) in non-diabetic subjects so that early intervention could be started. Design and Settings: A cross-sectional study was conducted in the clinical research department of a hospital in Taiwan from 2010 to 2011. Methods: A total of 89 subjects without diabetes were enrolled in the study, including 49 with normal glucose tolerance and 40 pre-diabetes. A frequently sampled intravenous glucose tolerance test was done to determine insulin sensitivity and acute insulin response after the glucose load, which is regarded as the 1st ISEC. Subjects with the lowest tertile of the 1st ISEC were defined as ISEC-D. From the simplest to the most complex, 3 models were build: Model 0: fasting plasma glucose (FPG); Model 1: FPG + body mass index (BMI) + High-density lipoprotein cholesterol (HDL-C); Model 2: Model 1+ fasting plasma insulin (FPI). The area under the receiveroperating characteristic curve (aROC curve) was used to determine the predictive power among these models. An optimal cut-off value was also determined. Results: Among metabolic syndrome (MetS) components (FPG, BMI, and HDL-C), FPG had the greatest aROC curve (70.9%). Moreover, the aROC curves of Models 1 and 2 were all significantly greater than that of FPG (80.4% and 82.3%, respectively). Their aROC curves were also greater than that of the homeostasis model assessment b-cell (HOMA-b) function, which is the most commonly used method to evaluate b-cell function. Conclusion: By using only MetS components, ISEC-D could be predicted with an acceptable sensitivity of 84.0% and a specificity of 74.0%. However, after adding FPI into the Model, the predictive power of Model 2 did not increase. These model-derived MetS components could be widely used in clinical settings and early detection of non-diabetic subjects with high risk for T2DM.

Original languageEnglish
Pages (from-to)138-145
Number of pages8
JournalAnnals of Saudi Medicine
Volume35
Issue number2
DOIs
Publication statusPublished - Mar 1 2015
Externally publishedYes

Fingerprint

Type 2 Diabetes Mellitus
Fasting
Insulin
Glucose
HDL Cholesterol
Insulin Resistance
Body Mass Index
Hospital Departments
Glucose Tolerance Test
Taiwan
Homeostasis
Cross-Sectional Studies
Research

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{980ee5ce1507409fb602a8e51a830142,
title = "Levels of the first-phase insulin secretion deficiency as a predictor for type 2 diabetes onset by using clinical-metabolic models",
abstract = "Aims: Type 2 diabetes mellitus (T2DM) is characterized by both decreased insulin sensitivity and impaired insulin secretion. The 2 phases of insulin secretion are the first-phase insulin secretion (1st ISEC) and the secondphase insulin secretion. In this study, we tried to build clinical-metabolic models to predict the 1st ISEC deficiency (ISEC-D) in non-diabetic subjects so that early intervention could be started. Design and Settings: A cross-sectional study was conducted in the clinical research department of a hospital in Taiwan from 2010 to 2011. Methods: A total of 89 subjects without diabetes were enrolled in the study, including 49 with normal glucose tolerance and 40 pre-diabetes. A frequently sampled intravenous glucose tolerance test was done to determine insulin sensitivity and acute insulin response after the glucose load, which is regarded as the 1st ISEC. Subjects with the lowest tertile of the 1st ISEC were defined as ISEC-D. From the simplest to the most complex, 3 models were build: Model 0: fasting plasma glucose (FPG); Model 1: FPG + body mass index (BMI) + High-density lipoprotein cholesterol (HDL-C); Model 2: Model 1+ fasting plasma insulin (FPI). The area under the receiveroperating characteristic curve (aROC curve) was used to determine the predictive power among these models. An optimal cut-off value was also determined. Results: Among metabolic syndrome (MetS) components (FPG, BMI, and HDL-C), FPG had the greatest aROC curve (70.9{\%}). Moreover, the aROC curves of Models 1 and 2 were all significantly greater than that of FPG (80.4{\%} and 82.3{\%}, respectively). Their aROC curves were also greater than that of the homeostasis model assessment b-cell (HOMA-b) function, which is the most commonly used method to evaluate b-cell function. Conclusion: By using only MetS components, ISEC-D could be predicted with an acceptable sensitivity of 84.0{\%} and a specificity of 74.0{\%}. However, after adding FPI into the Model, the predictive power of Model 2 did not increase. These model-derived MetS components could be widely used in clinical settings and early detection of non-diabetic subjects with high risk for T2DM.",
author = "Lin, {Jiunn Diann}",
year = "2015",
month = "3",
day = "1",
doi = "10.5144/0256-4947.2015.138",
language = "English",
volume = "35",
pages = "138--145",
journal = "Annals of Saudi Medicine",
issn = "0256-4947",
publisher = "Medknow Publications and Media Pvt. Ltd",
number = "2",

}

TY - JOUR

T1 - Levels of the first-phase insulin secretion deficiency as a predictor for type 2 diabetes onset by using clinical-metabolic models

AU - Lin, Jiunn Diann

PY - 2015/3/1

Y1 - 2015/3/1

N2 - Aims: Type 2 diabetes mellitus (T2DM) is characterized by both decreased insulin sensitivity and impaired insulin secretion. The 2 phases of insulin secretion are the first-phase insulin secretion (1st ISEC) and the secondphase insulin secretion. In this study, we tried to build clinical-metabolic models to predict the 1st ISEC deficiency (ISEC-D) in non-diabetic subjects so that early intervention could be started. Design and Settings: A cross-sectional study was conducted in the clinical research department of a hospital in Taiwan from 2010 to 2011. Methods: A total of 89 subjects without diabetes were enrolled in the study, including 49 with normal glucose tolerance and 40 pre-diabetes. A frequently sampled intravenous glucose tolerance test was done to determine insulin sensitivity and acute insulin response after the glucose load, which is regarded as the 1st ISEC. Subjects with the lowest tertile of the 1st ISEC were defined as ISEC-D. From the simplest to the most complex, 3 models were build: Model 0: fasting plasma glucose (FPG); Model 1: FPG + body mass index (BMI) + High-density lipoprotein cholesterol (HDL-C); Model 2: Model 1+ fasting plasma insulin (FPI). The area under the receiveroperating characteristic curve (aROC curve) was used to determine the predictive power among these models. An optimal cut-off value was also determined. Results: Among metabolic syndrome (MetS) components (FPG, BMI, and HDL-C), FPG had the greatest aROC curve (70.9%). Moreover, the aROC curves of Models 1 and 2 were all significantly greater than that of FPG (80.4% and 82.3%, respectively). Their aROC curves were also greater than that of the homeostasis model assessment b-cell (HOMA-b) function, which is the most commonly used method to evaluate b-cell function. Conclusion: By using only MetS components, ISEC-D could be predicted with an acceptable sensitivity of 84.0% and a specificity of 74.0%. However, after adding FPI into the Model, the predictive power of Model 2 did not increase. These model-derived MetS components could be widely used in clinical settings and early detection of non-diabetic subjects with high risk for T2DM.

AB - Aims: Type 2 diabetes mellitus (T2DM) is characterized by both decreased insulin sensitivity and impaired insulin secretion. The 2 phases of insulin secretion are the first-phase insulin secretion (1st ISEC) and the secondphase insulin secretion. In this study, we tried to build clinical-metabolic models to predict the 1st ISEC deficiency (ISEC-D) in non-diabetic subjects so that early intervention could be started. Design and Settings: A cross-sectional study was conducted in the clinical research department of a hospital in Taiwan from 2010 to 2011. Methods: A total of 89 subjects without diabetes were enrolled in the study, including 49 with normal glucose tolerance and 40 pre-diabetes. A frequently sampled intravenous glucose tolerance test was done to determine insulin sensitivity and acute insulin response after the glucose load, which is regarded as the 1st ISEC. Subjects with the lowest tertile of the 1st ISEC were defined as ISEC-D. From the simplest to the most complex, 3 models were build: Model 0: fasting plasma glucose (FPG); Model 1: FPG + body mass index (BMI) + High-density lipoprotein cholesterol (HDL-C); Model 2: Model 1+ fasting plasma insulin (FPI). The area under the receiveroperating characteristic curve (aROC curve) was used to determine the predictive power among these models. An optimal cut-off value was also determined. Results: Among metabolic syndrome (MetS) components (FPG, BMI, and HDL-C), FPG had the greatest aROC curve (70.9%). Moreover, the aROC curves of Models 1 and 2 were all significantly greater than that of FPG (80.4% and 82.3%, respectively). Their aROC curves were also greater than that of the homeostasis model assessment b-cell (HOMA-b) function, which is the most commonly used method to evaluate b-cell function. Conclusion: By using only MetS components, ISEC-D could be predicted with an acceptable sensitivity of 84.0% and a specificity of 74.0%. However, after adding FPI into the Model, the predictive power of Model 2 did not increase. These model-derived MetS components could be widely used in clinical settings and early detection of non-diabetic subjects with high risk for T2DM.

UR - http://www.scopus.com/inward/record.url?scp=84941614050&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941614050&partnerID=8YFLogxK

U2 - 10.5144/0256-4947.2015.138

DO - 10.5144/0256-4947.2015.138

M3 - Article

C2 - 26336020

AN - SCOPUS:84941614050

VL - 35

SP - 138

EP - 145

JO - Annals of Saudi Medicine

JF - Annals of Saudi Medicine

SN - 0256-4947

IS - 2

ER -